Last reviewed · How we verify

AZD6094

Samsung Medical Center · Phase 2 active Small molecule

AZD6094 is a CD73 inhibitor Small molecule drug developed by Samsung Medical Center. It is currently in Phase 2 development for Metastatic non-small cell lung cancer, Metastatic melanoma. Also known as: Volitinib, Savolitinib, HMPL - 504.

AZD6094 is a small molecule inhibitor of the CD73 enzyme.

AZD6094 is a small molecule inhibitor of the CD73 enzyme. Used for Metastatic non-small cell lung cancer, Metastatic melanoma.

Likelihood of approval
13.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Oncology Phase 2 attrition -2.0pp
    Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameAZD6094
Also known asVolitinib, Savolitinib, HMPL - 504
SponsorSamsung Medical Center
Drug classCD73 inhibitor
TargetCD73
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

CD73 is an enzyme involved in the production of adenosine, which plays a role in immune suppression. By inhibiting CD73, AZD6094 aims to reduce adenosine levels and enhance anti-tumor immune responses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about AZD6094

What is AZD6094?

AZD6094 is a CD73 inhibitor drug developed by Samsung Medical Center, indicated for Metastatic non-small cell lung cancer, Metastatic melanoma.

How does AZD6094 work?

AZD6094 is a small molecule inhibitor of the CD73 enzyme.

What is AZD6094 used for?

AZD6094 is indicated for Metastatic non-small cell lung cancer, Metastatic melanoma.

Who makes AZD6094?

AZD6094 is developed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).

Is AZD6094 also known as anything else?

AZD6094 is also known as Volitinib, Savolitinib, HMPL - 504.

What drug class is AZD6094 in?

AZD6094 belongs to the CD73 inhibitor class. See all CD73 inhibitor drugs at /class/cd73-inhibitor.

What development phase is AZD6094 in?

AZD6094 is in Phase 2.

What are the side effects of AZD6094?

Common side effects of AZD6094 include Fatigue, Nausea, Diarrhea.

What does AZD6094 target?

AZD6094 targets CD73 and is a CD73 inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing